Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04760288
Title A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC)
Acronym AcceleRET-MTC
Recruitment Withdrawn
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries ESP

Facility Status City State Zip Country Details
Hospital Universitario Virgen del Rocio Sevilla 41013 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field